Clostridium difficile ClpP Homologues are Capable of Uncoupled Activity and Exhibit Different Levels of Susceptibility to Acyldepsipeptide Modulation
Lavey, N.P.; Shadid, T.; Ballard, J.D.; Duerfeldt, A.S.
ACS Infec. Dis., 2019, 5, 79.
Read Publication
Structure-guided Evolution of a 2-Phenyl-4-carboxyquinoline Chemotype into PPAR-alpha Selective Agonists: New Leads for Oculovascular Conditions
Dou, X.; Nath, D.; Shin, Y; Ma, J.; Duerfeldt, A.S.
Bioorg. Med. Chem. Lett., 2018, 28, 2717.
Read Publication
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 to Optimize Paralog-Selective Binding
Que, N.L.S.; Crowley, V.M.; Duerfeldt, A.S.; Zhao, J.; Kent, C.N.; Blagg, B.S.J.; Gewirth, D.T.
J. Med. Chem., 2018, 61, 2793.
Read Publication
Consequences of Depsipeptide Substitution on the ClpP Activation Activity of Antibacterial Acyldepsipeptides
Li, Y.; Lavey, N.P.; Coker, J.A,; Knobbe, J.E.; Truong, D.C.; Yu, H.; Lin, Y.S.; Nimmo, S.l.; Duerfeldt, A.S.
ACS Med. Chem. Lett., 2017, 8, 1171.
Read Publication
Recent Advances Towards Rational Antibacterial Discovery: Addressing Permeation and Efflux
Avila, Q.P.; Zgurskaya, H.I.; Duerfeldt, A.S.
ACS Med. Chem. Reviews, 2017, 52, 319.
Read Publication
Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease P
Lavey, N.P.; Coker, J.A.; Ruben, E.A.; Duerfeldt, A.S.
J. Nat. Prod., 2016, 79, 1193.
Read Publication
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold
Crowley, V.M.; Khandelwal, A.; Mishra, S.; Stothert, A.R.; Huard, D.J.E.; Zhao, J.; Muth, A.; Duerfeldt, A.S.; Kizziah, J.L.; Lieberman, R.L.; Dickey, C.A.; Blagg, B.S.J.
J. Med. Chem., 2016, 59, 3471.
Read Publication
Grp94 Delivers gamma-aminobutyric Acid Type A (GABA) Receptors to Hrd1-Mediated Endoplasmic Reticulum-Associated Degradation
Di, X.J.; Wang, Y.J.; Han, D.Y.; Fu, Y.L.; Duerfeldt, A.S.; Blagg, B.S.J.; Mu, T.W.
J. Biol. Chem., 2016, 291, 9526.
Read Publication
Cycloadditions of Noncomplementary Substituted 1,2,3-Triazines
Anderson, E.A.; Duerfeldt, A.S.; Zhu, K.; Glinkerman, C.M.; Boger, D.L.
Org. Lett., 2014, 16, 5084–5087.
Read Publication
Stereoselective Syntheses of (–)-Pyrimidoblamic Acid and P-3A
Fundamental Relationship Between Hydrophobic Properties and Biological Activity for the Duocarmycin Class of DNA Alkylating Antitumor Drugs: Hydrophobic Binding-Driven-Bonding
Wolfe, A.L., Duncan, K.K., Lajiness, J.P., Zhu, K., Duerfeldt, A.S., Boger, D.L.
J. Med. Chem., 2013, 56, 6845–6857.
Read Publication
Glucose-regulated Protein 94 Triage of Mutant Myocilin through Endoplasmic Reticulum-associated Degradation Subverts a More Efficient Autophagic Clearance Mechanism
Suntharalingam, A.; Abisambra, J.F.; O’Leary, J.C.; Koren III, J.; Zhang. B.; Kuk Joe, M.; Blair, L.J.; Hill, S.E.; Jinwal, U.K.; Cockman, M.; Duerfeldt, A.S.; Tomarev, S.; Blagg, B.S.J.; Lieberman, R.L.; Dickey, C.A.
J. Biol. Chem., 2012, 287, 40661–40669.
Read Publication
Development of a Grp94 Inhibitor
Duerfeldt, A.S.; Peterson, L.B.; Maynard, J.C.; Ng, C.L.; Eletto, D.; Ostrovsky, O.; Shinogle, H.E.; Moore, D.S.; Argon, Y.; Nicchitta, C.V.; Blagg, B.S.J.
J. Am. Chem. Soc., 2012, 134, 9796–9804.
Read Publication
Synthesis and Biological Evaluation of Arylated Novobiocin Analogs as Hsp90 Inhibitors
Kusuma, B.R.; Duerfeldt, A.S.; Blagg, B.S.J.
Bioorg. & Med. Chem. Lett., 2011, 21, 7170–7174.
Read Publication
Hsp90 Inhibition: Elimination of Shock and Stress
Design, Synthesis and Biological Activity of Bicyclic Radester Analogues as Hsp90 Inhibitors
Jadhav, V.; Duerfeldt, A.S. Blagg, B.S.J.
Bioorg. & Med. Chem. Lett., 2009, 19, 6845−6850.
Read Publications
Design, Synthesis and Biological Evaluation of Conformationally Constrained cis-Amide Inhibitors.
